Castle Biosciences reports Q3 2026 revenue of $102.9M and raises full-year guidance
FROM THE WIRE · PRNEWSWIRE.COM
Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million Conference call and webcast today at 4:30 p.m. ET…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaising full-year revenue guidance is a positive signal for the stock, though the company is small-cap.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 2026 revenue was $102.9 million, up 24% year over year.
- 02TissueCypher test report volume increased 47% over Q3 2025.
- 03Full-year 2026 revenue guidance was raised to $385-395 million from $365-375 million.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets